Personalized prostate cancer diagnosis and treatment—are we ready?

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. Ca Cancer J Clin. 2017;67:7–30. CrossRefPubMed

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–29. CrossRefPubMed

Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schafer G, Frauscher F, Boniol M, Severi G, Robertson C, Boyle P, Tyrol Prostate Cancer Screening Group. Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality. Cancer. 2008;101:809–16.

Phillips R. Prostate cancer: PSA update—no change yet. Nat Rev Urol. 2014;11:483. CrossRefPubMed

Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A, Investigators E. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–35. CrossRefPubMedPubMedCentral

Thompson J, Lawrentschuk N, Frydenberg M, Thompson L, Stricker P, USANZ. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int. 2013;112(Suppl 2):6–20. CrossRefPubMed

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow A, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2018;73:178–211. CrossRefPubMed

Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP. Local treatment for metastatic prostate cancer: a systematic review. Int J Urol. 2018;25:390–403. CrossRefPubMed

Heidegger I, Heidenreich A, Pfister D. New biomarkers for selecting the best therapy regimens in metastatic castration-resistant prostate cancer. Target Oncol. 2017;12:37–45. CrossRefPubMed

Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol. 2013;138:248–56. CrossRefPubMedPubMedCentral

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Kumar AR, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. lancet Oncol. 2018;19:825–33. CrossRefPubMed

von Frieling J, Fink C, Hamm J, Klischies K, Forster M, Bosch TCG, Roeder T, Rosenstiel P, Sommer F. Grow with the challenge—microbial effects on epithelial proliferation, carcinogenesis, and cancer therapy. Front Microbiol. 2018;9:2020. CrossRef